Name | Jeanne Jugan Residence |
---|---|
Location | 2999 Schurz Avenue, Bronx, New York |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 30 |
Occupancy Rate | 73% |
Medicare ID (CCN) | 335849 |
Legal Business Name | Home For The Aged Of The Little Sisters Of The Poor Of The City Of Ny |
Ownership Type | Non Profit - Corporation |
NPI Number | 1184734220 |
Organization Name | HOME FOR THE AGED OF THE LITTLE SISTERS OF THE POOR OF THE CITY OF NY |
Doing Business As | JEANNE JUGAN RESIDENCE, BRONX |
Address | 2999 Schurz Ave, Bronx, NY 10465 |
Phone Number | 347-329-1800 |
News Archive
In the midst of the most vigorous national health care debate in 15 years, and at a time of heightened economic insecurity, new data on employers show that the health of employed American workers is trending downward in a number of important areas. The State of Health in the American Workforce, a report released today by the Families and Work Institute (FWI), finds that only 28% of employees today report that their overall health is "excellent," down from 34% just six years ago.
Riverain Medical announced today that the U.S. Food and Drug Administration has granted approval for the newest version of the OnGuard Chest X-ray Computer-Aided Detection technology. OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. This improved performance demonstrates a 73% reduction in false positive marks and 50% higher relative sensitivity compared to the original product.
Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
In the midst of the most vigorous national health care debate in 15 years, and at a time of heightened economic insecurity, new data on employers show that the health of employed American workers is trending downward in a number of important areas. The State of Health in the American Workforce, a report released today by the Families and Work Institute (FWI), finds that only 28% of employees today report that their overall health is "excellent," down from 34% just six years ago.
Riverain Medical announced today that the U.S. Food and Drug Administration has granted approval for the newest version of the OnGuard Chest X-ray Computer-Aided Detection technology. OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. This improved performance demonstrates a 73% reduction in false positive marks and 50% higher relative sensitivity compared to the original product.
Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $8518 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 2.94 | 14.46 |
Percentage of long-stay residents who lose too much weight | 7.77 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 12.12 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.96 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.95 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.14 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 0 | 14.2 |